A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs VE 303 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONSORTIUM
- Sponsors Vedanta Biosciences
- 23 Sep 2019 According to a Vedanta Biosciences media release, the funding from recent series C-2 financing ($16.6 million) will support this trial.
- 12 Sep 2019 Planned number of patients changed from 146 to 300.
- 12 Dec 2018 Status changed from planning to recruiting, according to a PureTech Health media release.